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ABSTRACT 
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A major limitation of some of the most effective breast cancer (BC) therapies is the development of 
heart failure or left ventricular dysfunction.  However, knowledge of the risk factors for development 
of cardiotoxicity from use of current standard BC therapies is incomplete.  This study aimed to 
determine the incidence and predictors of cardiotoxicity associated with anthracycline and 
trastuzumab treatment.   
We retrospectively identified patients in the Yale Nuclear Cardiology database who were diagnosed 
with BC between 2003 and 2013.  The patients were grouped into cohorts based on whether they had 
received an anthracycline or trastuzumab as a part of their treatment regimen.  As some patients had 
received both of these agents, the cohorts were not mutually exclusive.  The independent variables of 
interest were baseline patient characteristics and comorbidities, baseline cardiac imaging parameters, 
and treatment factors (radiotherapy, cumulative anthracycline dose, and treatment with other agents).  
The endpoint was development of cardiotoxicity, as defined by a new diagnosis of congestive heart 
failure (CHF), admission for an acute CHF exacerbation, or a significant pre-defined decline in left 
ventricular ejection fraction.   
We identified 571 women with BC.  In the anthracycline cohort, patients were 50.84 years old on 
average (SD: 9.65, n = 496).  The 3-year cumulative incidences of cardiotoxicity in the anthracycline 
and trastuzumab cohorts were 12.70 and 42.54 cardiac events per 100 people, respectively.  The 
results of a multivariate Cox proportional-hazards regression analysis suggested that  receipt of 
bevacizumab or trastuzumab independently increased the risk of cardiotoxicity in patients treated with 
an anthracycline (HR: 4.70, 95% CI for HR: 1.78-12.44, p-value: 0.002 or HR: 10.51, 95% CI for HR: 
5.83-18.93, p-value: < 0.001, respectively).  In the trastuzumab cohort, the mean age was 52.01 (SD: 
10.66, n = 134).  In a similar multivariate analysis, anthracycline was not shown to increase the 
incidence of cardiotoxicity in patients who received trastuzumab, regardless of the cumulative 
anthracycline dose level (≤ 240 mg/m
2
 or > 240 mg/m
2
).  However, dyslipidemia was a significant 
risk factor (HR: 3.66, 95% CI for HR: 1.80-7.42, p-value: < 0.001).  Interestingly, use of radiotherapy 
was associated with a lower incidence of developing cardiotoxicity in the anthracycline and 
trastuzumab cohorts, irrespective of the laterality of radiotherapy.  A positive smoking history was 
related to a shorter time to cardiotoxicity for both the anthracycline and trastuzumab cohorts (HR: 
2.82, 95% CI for HR: 1.39-5.71, p-value: 0.0039 and HR: 3.01, 95% CI for HR: 1.42-6.39, p-value: 
0.0040, respectively).  In the anthracycline cohort, an abnormal baseline left ventricular end-diastolic 
volume and an abnormal baseline peak filling rate were not significantly associated with 
cardiotoxicity. 
In conclusion, trastuzumab and bevacizumab significantly increase risk of cardiotoxicity in patients 
who receive an anthracycline.  Smoking and dyslipidemia are potential targets for risk reduction.  The 
lack of a significant cardiotoxic effect associated with radiotherapy suggests that previously accepted 
beliefs regarding radiotherapy’s harmful cardiac effects when used for BC treatment may be outdated, 
although further analysis in larger groups and accounting for additional confounding variables is 
necessary.  Future studies are necessary to re-evaluate modern radiotherapy’s cardiac effects. 
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INTRODUCTION 
Despite improved screening measures and the ability to detect disease at an earlier stage, 
breast cancer continues to place a significant burden on public health (1).  It accounts for 
23% of cancer cases and is the most common cause of cancer-related deaths in women 
globally (2).  However, scientific advancements continue to expand our understanding of 
its pathological characteristics, and we now have a more diverse arsenal of breast cancer 
treatments.   These include, but are not limited to, chemotherapeutic agents such as 
taxanes, anthracyclines, 5-fluorouracil, capecitabine, and cyclophosphamide; endocrine 
agents such as aromatase inhibitors and tamoxifen; monoclonal antibodies such as 
trastuzumab; antiangiogenic compounds such as bevacizumab; and radiotherapy. 
Fortunately, these breast cancer treatments have improved disease-free and overall 
survival (3-6).  For instance, the NOAH trial found that in patients with HER2-positive 
breast cancer who received trastuzumab, the 3-year event-free survival was 71% (3).  
This was significantly higher than the 3-year event-free survival of 56% in those who had 
not received trastuzumab (3).  A pooled analysis also found that higher cumulative 
anthracycline doses were significantly associated with pathological complete response 
(pCR), particularly in HER2-negative patients (7).  The same analysis found other factors 
related to chemotherapy, such as an increased number of chemotherapy cycles in 
hormone receptor (HR)-positive patients, were significantly associated with pCR as well 
(7).  Though the BEATRICE trial did not demonstrate improved invasive disease-free 
survival with the addition of bevacizumab to adjuvant therapy in those with triple-
negative breast cancer (8), the GeparQuinto trial and NSABP B40 trials did demonstrate 
significantly increased rates of pCR when bevacizumab was used in the neoadjuvant 
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setting (9, 10).  While data on whether pCR can be used as a reliable surrogate outcome 
marker at the trial-level have been mixed (11-14), pCR may have an individual-level 
association with long-term outcome (12, 13).  Thus, the positive associations between the 
mentioned breast cancer treatments and pCR are encouraging. 
The benefits of the currently available breast cancer treatment regimens are significant; 
however, one of the major non-malignant complications of these breast cancer therapies 
is development of heart failure or ventricular dysfunction (15).  While these 
developments can be asymptomatic, some are life-threatening and dose-limiting (15).  
Anthracycline is one such chemotherapeutic agent used for multiple types of cancer, 
including breast cancer (16).  Those who receive anthracycline-based therapies for these 
various cancers are approximately five times as likely to develop cardiotoxicity than 
those who receive non-anthracycline-based therapies (16).  Importantly, asymptomatic 
cases of cardiotoxicity can progress to irreversible congestive heart failure (CHF) (15).  
In addition, the survival associated with doxorubicin-induced cardiomyopathy is worse 
than the survival associated with ischemic cardiomyopathy, one of the most common 
causes of cardiomyopathy (17).    
The putative mechanism behind anthracycline-induced cardiotoxicity continues to be 
debated.  It had long been believed that anthracycline’s cardiotoxic effects were mediated 
by the production of reactive oxygen species (ROS) and increased oxidative stress, 
ultimately leading to myofibril loss and myocardial vacuolization (18, 19).  However, 
several studies assessing the efficacy of anti-ROS agents such as iron chelators have 
failed to demonstrate complete protection against doxorubicin-induced cardiotoxicity (19, 
20).  Rather, the fundamental mechanism of cardiac injury appears to involve the 
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topoisomerase-II (Top2) enzyme.  Top2α is overexpressed in proliferating cells such as 
cancer cells but otherwise is not normally detectable (18).(21)  Doxorubicin binds to this 
enzyme and DNA, forming a ternary cleavage complex that subsequently activates cell 
death (18).  However, doxorubicin also binds to Top2β, which is normally expressed in 
adult cardiomyocytes (18, 21, 22).  The implications of this interaction have been studied 
by Zhang et al., who developed a murine model where cardiomyocyte-specific Top2β 
was deleted (18).  They found that this deletion protected cardiomyocytes not only from 
DNA double-stranded breaks and transcriptome changes promoting ROS formation but 
also from progressive heart failure following doxorubicin exposure (18).      
Trastuzumab is also associated with cardiotoxicity (15).  A meta-analysis found that 
trastuzumab increased the risk of CHF and declines in left ventricular ejection fraction 
(LVEF) by 5.11 and 1.83 times, respectively, when compared to regimens without 
trastuzumab (23).  The mechanism of trastuzumab-induced cardiotoxicity has not been 
completely established, but ErbB2 (HER2/neu) signaling has been implicated.  In a 
mouse model, ErbB2-deficient mice developed dilated cardiomyopathy and increased 
susceptibility to anthracycline-induced cardiotoxicity (24).  Other studies in mice also 
revealed HER2 signaling to have an important role in proper embryonic cardiac 
development (25, 26).  
Risk factors for trastuzumab- and anthracycline-induced cardiotoxicity have been studied, 
and several have been reported (15, 27, 28).  For instance, radiotherapy in patients treated 
with high-dose anthracycline regimens has been associated with subsequent development 
of cardiotoxicity (29).  Higher cumulative anthracycline doses, lengthier durations of 
trastuzumab therapy, and concomitant trastuzumab and anthracycline treatment regimens 
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have also been associated with development of cardiotoxicity (15).  Still, the risk factors 
for developing cardiotoxicity have not been completely defined (30).  Previous studies 
that aimed to identify risk factors may also be outdated, such as those that involved pre-
modern radiotherapy techniques (30).   Left-sided radiotherapy can expose the heart to a 
greater mean dose of radiation than right-sided radiotherapy due to the heart’s anatomic 
position (31), and therefore left-sided radiotherapy may increase a patient’s risk for 
developing heart disease.  However, this may not be the case in the modern era of 
radiotherapy, as the incidental radiation to the heart has now been decreased significantly 
(30).  Furthermore, there have been few studies on baseline equilibrium radionuclide 
angiocardiography (ERNA) imaging parameters as potential predictors of clinically 
significant anthracycline- or trastuzumab-induced cardiotoxicity.  While baseline left 
ventricular ejection fraction is typically evaluated before a patient begins an 
anthracycline or trastuzumab, other imaging parameters (such as baseline peak filling rate 
and left ventricular end diastolic volume) as potential predictors of cardiotoxicity have 
not been as well studied. 
These deficiencies are reflected by the lack of detailed guidelines for noninvasive cardiac 
monitoring in patients treated with cardiotoxic breast cancer therapies (30).  Better 
characterization of the risk factors and predictors for cardiotoxicity associated with 
modern-day breast cancer therapies is critical for risk-reduction efforts and for 
identifying individuals who may need more stringent monitoring of cardiac function.  
This would allow earlier detection of cardiotoxicity and subsequent intervention in those 
patients who would most benefit from being subjected to more frequent cardiac 
evaluations.  Early detection of cardiotoxicity is critical since cardioprotective 
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interventions implemented at the subclinical stage can be more effective than when 
implemented during its later, symptomatic stages (32).    
STATEMENT OF PURPOSE AND HYPOTHESES 
In this study, we sought to determine the incidence of and risk factors for cardiotoxicity, 
as defined by a change in ejection fraction or development of CHF symptoms, associated 
with current anthracycline- or trastuzumab-based breast cancer therapies.  We also aimed 
to evaluate baseline imaging parameters as potential predictors of cardiotoxicity.  The 
overarching goal was to identify patients who may require risk management and/or more 
rigorous cardiac monitoring so that they can continue to benefit from the effective 
anthracycline- or trastuzumab-based breast cancer therapies. 
Our hypotheses were the following: 
 Given the development of approaches to reduce cardiotoxicity such as more 
targeted radiotherapy techniques (30), the incidence of anthracycline- and 
trastuzumab-induced cardiotoxicity is now lower than previously published 
incidences. 
 Increased age, increased BMI, a positive family history of cardiac disease, a 
positive smoking history, and renal/cardiovascular/liver comorbidities are 
associated with increased risk for developing anthracycline- or trastuzumab-
induced cardiotoxicity. 
 Abnormal left ventricular ejection fraction, peak filling rate, and left ventricular 
end-diastolic volume on baseline equilibrium radionuclide angiocardiography are 
predictors of cardiotoxicity. 
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 Left-sided chest radiotherapy is associated with increased risk for developing 
anthracycline- or trastuzumab-induced cardiotoxicity. 
 The risk for developing anthracycline-induced cardiotoxicity increases as the 
cumulative dose increases. 
 Additional treatment (such as trastuzumab, anthracycline, and/or bevacizumab) 
increases the risk of developing cardiotoxicity in those who receive trastuzumab 
or anthracycline. 
METHODS 
Data Sources 
Data were obtained from the Yale Nuclear Cardiology database, which contains limited 
data on patients’ characteristics, comorbidities, and equilibrium radionuclide 
angiocardiography (ERNA) findings.  The Yale Nuclear Cardiology database was used 
for two reasons.  Firstly, until approximately two years ago, ERNA was the preferred 
method of measuring left ventricular systolic and diastolic function in patients receiving 
chemotherapy at Yale.  Secondly, the echocardiography reporting system is not 
configured to search reliably for patients based on whether they will or have received 
chemotherapy. 
Medical records from Yale-New Haven Hospital, Hospital of Saint Raphael, Yale 
Smilow Cancer Hospital, and Yale Cancer Care Centers were also reviewed to obtain 
more complete data about patients’ comorbidities, imaging, and treatment histories.  The 
Yale University Human Investigation Committee approved this medical record review 
(HIC #1303011697).  While I performed most of the retrospective chart review, Igor 
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Medic, MD; Raymond Russell, MD; and Sara Anwar, MD, also participated during the 
initial stages.   
Study Sample 
Breast cancer patients who received anthracycline (doxorubicin, Doxil, or epirubicin) 
and/or trastuzumab as a part of their treatment and whose baseline LVEF was determined 
by ERNA were included in the study.  Patients were excluded if they met any of the 
following criteria: 1) received any chemotherapy or radiotherapy prior to their baseline 
ERNA, 2) had a prior diagnosis of a cancer that typically requires chemotherapy or 
radiotherapy, or 3) received dexrazoxane during chemotherapy for their breast cancer.   
Study Design 
This was a retrospective study, where the endpoint and outcome variable was 
cardiotoxicity, as indicated by a cardiac event.  Data on baseline patient risk factors and 
various treatment factors were extracted using a chart abstraction tool that I created for 
consistency.  Patients were sub-grouped into two cohorts.  The anthracycline cohort 
consisted of patients who received an anthracycline, regardless of whether or not 
trastuzumab was also a part of their treatment regimen.  The trastuzumab cohort consisted 
of patients who received trastuzumab, regardless of whether or not they received an 
anthracycline.  These cohorts were therefore not mutually exclusive.  However, they 
allowed me to identify risk factors specific for developing anthracycline-associated 
cardiotoxicity and those specific for developing trastuzumab-associated cardiotoxicity in 
our study sample.  The length of follow-up was calculated as the time between the start of 
chemotherapy, trastuzumab, or bevacizumab and the date of the last clinic/admission note 
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or imaging study (echocardiogram or ERNA).  The time to event was calculated as the 
time between the start of chemotherapy, trastuzumab, or bevacizumab and the date of a 
cardiac event. 
Study Variables 
Baseline patient characteristics and comorbidities 
The following baseline patient risk factors were obtained from the Yale Nuclear 
Cardiology database: age, body mass index (BMI), and family history of cardiac disease.  
The following baseline patient risk factors were obtained from review of the medical 
records: history of dyslipidemia, hypertension, diabetes mellitus, smoking, coronary 
artery disease, valvular heart disease, atrial fibrillation, peripheral vascular disease, liver 
disease (transient or chronic), stroke or transient ischemic attack, and chronic renal 
failure.  A patient who was a current smoker or had quit smoking in the past year prior to 
the baseline ERNA study was considered to have a positive smoking history. 
Baseline imaging parameters 
The following baseline imaging parameters were obtained from ERNA results in the Yale 
Nuclear Cardiology database: peak filling rate (PFR), left ventricular ejection fraction 
(LVEF), and LV end-diastolic volume (EDV).  Abnormal values for PFR, LVEF, and LV 
EDV are < 2.5 EDV/sec, < 50%, and ≥140 mL respectively. 
Treatment factors 
Detailed treatment histories were abstracted from the medical records.  They included 
whether or not the patient received axillary, regional lymph node, and/or chest/breast wall 
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radiotherapy for her breast cancer.  If such radiotherapy was given, the laterality was 
recorded (right only, left only, or both sides).  The cumulative anthracycline dose was 
also recorded.  Epirubicin doses were converted to doxorubicin equivalents according to 
the Children’s Oncology Group Long-Term Follow-Up Guidelines for Survivors of 
Childhood, Adolescent, and Young Adult Cancers (Version 3.0) (33). 
Additional treatment as a risk factor for cardiotoxicity was also considered.  In the 
anthracycline cohort, additional treatment was considered to be bevacizumab or 
trastuzumab.  None of the patients in our study received both bevacizumab and 
trastuzumab.  The groups in this additional treatment variable were therefore mutually 
exclusive and consisted of patients who received (1) no additional treatment, (2) 
bevacizumab, or (3) trastuzumab.  In the trastuzumab group, additional treatment was 
considered to be anthracycline. 
Cardiac Event 
A cardiac event was defined as or indicated by a new diagnosis of CHF, admission for an 
acute CHF exacerbation, or a significant decline in LVEF on subsequent evaluations by 
echocardiography or ERNA.  A significant decline in LVEF in a patient with a normal 
baseline LVEF (≥ 50%) was considered to be a decrease of 10 or more percentage points 
from baseline or a decrease to below the institution’s lower limit of normal (50%).  A 
significant decline in a patient with an abnormal baseline LVEF (< 50%) was considered 
to be a decrease of 10 or more percentage points from baseline.  When a cardiac event 
could be classified as a decline in LVEF or a new diagnosis of CHF, the former 
classification was applied. 
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Assessment of Left Ventricular Function 
Parameters of left ventricular function were quantified by ERNA using serial 5- to 7-min 
acquisitions taken from the left anterior oblique view using a nuclear medicine camera 
(Myosite, GE Healthcare, Barrington, IL).  Red blood cells were labeled in vitro with 
925-1,110 MBq of 
99m
Tc-pertechnetate (UltraTag, Mallinckrodt Medical, St. Louis, MO).  
LV EDV was ascertained using the Massardo count ratio method (34), and LVEF and 
PFR were calculated using previously validated software based on time activity curves 
from a region of interest that included the left ventricular cavity (35). 
Statistical Analysis 
Incidence rates per person-month of follow-up and 3-year cumulative incidences were 
calculated for each treatment group.  Descriptive statistics were generated as frequencies 
for categorical variables and means and standard deviations for continuous variables.  
The variables were compared across the treatment groups using the chi-squared test when 
counts were above five or Fisher’s exact test when counts were five or below.  All 
continuous variables were categorized using established cutoff values for 
normal/abnormal levels in further analyses.  Additionally, within each cohort, the number 
of individuals and number of events were considered for each variable category.  
Variables with fewer than 5% of the cohort were categorized in any level were excluded 
from subsequent univariate and multivariate analyses, except for the radiotherapy 
variable.  In this case, rather than removing the entire variable, patients who received 
bilateral radiotherapy were removed from the multivariate analyses in both cohorts since 
this group included too few patients to be considered statistically relevant. 
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Unadjusted Kaplan-Meier curves were generated and between-group results were 
compared using log rank tests.  Cox proportional-hazards models were constructed to 
evaluate unadjusted relationships between variables meeting the criteria outlined above 
and the outcome.  Those variables shown to have statistically significant associations in 
the univariate analyses and variables with known clinical significance in relation to 
occurrence of cardiotoxicity were included in a multivariate Cox proportional-hazards 
regression model. 
To evaluate for the interaction of confounding variables when statistical significance 
changed between the adjusted and unadjusted analyses, bivariate Cox proportional hazard 
models were used.  Each potential confounder and the variable significantly associated 
with cardiotoxicity in the multivariate analysis only were modeled together to determine 
if the adjusted estimate for the effect of the variable was changed relative to the 
unadjusted estimate.  Statistical analyses were performed by Christos Hatzis, PhD, and 
Laura Skrip, MPH, using R Statistical Software version 3.0.1 (Foundation for Statistical 
Computing).  P-values less than 0.05 were considered statistically significant unless 
otherwise indicated. 
RESULTS 
We identified 571 patients in the Yale Nuclear Cardiology database who were diagnosed 
with breast cancer from 2003 through 2013 and met the criteria for inclusion in the 
analysis.  All patients who qualified for the study were female.  Four hundred ninety six 
patients received an anthracycline, and 134 patients made up the trastuzumab cohort. 
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Within the anthracycline cohort of 496 patients, 389 (78%) received an anthracycline but 
no bevacizumab or trastuzumab, 30 (6.0%) received anthracycline + bevacizumab (but no 
trastuzumab), and 76 (15%) received anthracycline + trastuzumab (but no bevacizumab) 
(Table 1a).  Data on additional treatment were missing for one patient receiving an 
anthracycline.  There were a total of 69 (13.9%) cardiac events in the anthracycline 
cohort.  All of them were due to significant declines in LVEF.  The frequency of 
cardiotoxicity did differ across treatment subgroups in the cohort (p < 0.001), with only 
6.94% of patients in the anthracycline-only subgroup experiencing an event, but 23.33% 
in the anthracycline + bevacizumab subgroup and 46.05% in the anthracycline + 
trastuzumab subgroup experiencing cardiotoxicity.   
The overall cardiotoxicity incidence rate and 3-year cumulative incidence in the 
anthracycline cohort were 0.0032 events/person-month and 12.70 cardiac events per 100 
people, respectively (Table 1a).  In the anthracycline-only, anthracycline + bevacizumab, 
and anthracycline + trastuzumab subgroups, the 3-year cumulative incidences were 5.91, 
23.33, and 43.42 cardiac events per 100 people, respectively (p < 0.001). 
Patients in the treatment subgroups of the anthracycline cohort did not significantly differ 
in terms of proportions of individuals presenting with risk factors, such as history of 
dyslipidemia, hypertension, diabetes mellitus, smoking, coronary artery disease, valvular 
heart disease, atrial fibrillation, peripheral vascular disease, liver disease (transient or 
chronic), stroke or transient ischemia attack, and chronic renal failure (Table 1a).  
Furthermore, they did not differ in terms of proportions of individuals with family 
histories of cardiac disease.  None of the patients in this cohort had valvular heart disease, 
and this was not included in Table 1a.  The subgroups were likewise similar in terms of 
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age (p = 0.75) and BMI (p = 0.76).  Most patients in the anthracycline cohort received 
radiotherapy and were similarly likely to have it on the left side only (34.89%) or right 
side only (32.66%).  This distribution did not significantly vary across treatment 
subgroups (p = 0.081).  The mean cumulative anthracycline dose received by patients 
differed significantly across subgroups (p = 0.013), but there was no significance seen 
when the cumulative anthracycline dose was categorized into ≤ 240 mg/m2 and > 240 
mg/m
2
 (p = 0.11).  The mean cumulative anthracycline dose received was 241.3± 24.75 
mg/m
2
 (range: 60 mg/m
2
-450 mg/m
2
).   
Table 1b provides a descriptive overview of the trastuzumab cohort.  Among the 134 
patients receiving trastuzumab, 76 (57%) also received an anthracycline, while 57 (43%) 
did not receive an anthracycline.  Data on additional treatment were missing for one 
patient receiving trastuzumab.  There were a total of 59 (44.03%) cardiac events in the 
trastuzumab cohort.  Two (3%) of these events were indicated by a CHF exacerbation-
related hospital admission, while 57 (97%) of them were due to significant declines in 
LVEF.  The proportion of individuals experiencing a cardiac event was over 40% in both 
groups and did not significantly differ between the two groups (p = 0.63).  As with the 
anthracycline cohort, patients receiving trastuzumab did not significantly differ in terms 
of the frequency of most risk factors considered.  It was observed, however, that patients 
who were on trastuzumab but not an anthracycline were more likely to have a history of 
chronic renal failure (10.53% versus 1.33%, p = 0.042).  Furthermore, on average, 
patients who were on trastuzumab but not an anthracycline were older (55.44 ±11.24 
years) than those receiving both trastuzumab and an anthracycline (49.47±9.58 years).  
Yet, the groups did not significantly differ in terms of the proportions of individuals over 
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65 years old – the age cutoff associated with increased risk of cardiac events.  The mean 
cumulative anthracycline dose among those who also received an anthracycline was 
239.9±19.1 mg/m
2
 (range: 120 mg/m
2
-310 mg/m
2
).  None of the patients had valvular 
heart disease, and this variable was excluded from the Table 1b.  
The overall cardiotoxicity incidence rate and 3-year cumulative incidence in the 
trastuzumab cohort were 0.02 events/person-month and 42.54 cardiac events per 100 
people, respectively (Table 1b).  In the trastuzumab without anthracycline and 
trastuzumab with anthracycline subgroups, the 3-year cumulative incidences were 52.27 
and 43.42 cardiac events per 100 people, respectively (p = 0.46). 
Overall, the median time to event was 10.9 months (range: 1.2-91.0), and the median 
follow-up length in those who did not experience a cardiac event was 48.3 months 
(range: 0.8-115.6).  In the anthracycline cohort, the median time to event was 9.0 months 
(range: 1.3-91.0), while the median follow-up length in those who did not experience a 
cardiac event was 47.0 months (range: 0.9-115.6).  In the trastuzumab cohort, the median 
time to event was 9.8 months (range: 1.2-91.0), while the median follow-up length in 
those who did not experience a cardiac event was 46.4 months (range: 0.8-99.6). 
Select Kaplan-Meier curves for significant univariate relationships between the covariate 
and the outcome variable are shown in Figures 1 and 2.  In the anthracycline cohort, there 
were significant differences in the cardiotoxicity-free survival curves associated with no 
additional treatment, bevacizumab as additional treatment, and trastuzumab as additional 
treatment (p < 0.001: Figure 1a).  Of the three, the group receiving anthracycline and 
trastuzumab exhibited the worst cardiotoxicity-free survival curve (Figure 1a).  
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Interestingly, in the trastuzumab cohort, anthracycline treatment was not associated with 
significantly worse cardiotoxicity-free survival compared to that for patients who did not 
receive an anthracycline (p = 0.99: Figure 2a).   
In both the anthracycline and trastuzumab cohorts, left-sided and right-sided radiotherapy 
were both significantly associated with better cardiotoxicity-free survival compared to no 
radiotherapy (anthracycline cohort: p < 0.001 for left-sided versus none, p < 0.001 for 
right-sided versus none; trastuzumab cohort: p < 0.001 for left-sided versus none, p = 
0.023 for right-sided versus none; Figures 1b and 2b).  The laterality of radiotherapy did 
not affect cardiotoxicity-free survival in either cohort (anthracycline cohort: p = 0.17 for 
left-sided versus right-sided; trastuzumab cohort: p = 0.15 for left-sided versus right-
sided; Figures 1b and 2b).  A history of dyslipidemia at baseline and age > 65 in those 
who received trastuzumab were associated with increased rates of cardiotoxicity 
compared to no history of dyslipidemia and age ≤ 65, respectively (p = 0.010 and p < 
0.001, respectively). 
In the multivariate Cox proportional-hazards regression analysis of the anthracycline 
cohort, bevacizumab and trastuzumab significantly increased the risk of cardiotoxicity by 
4.70- and 10.51-fold, respectively (HR: 4.70, 95% CI for HR: 1.78-12.44, p-value: 
0.0018 and HR: 10.51, 95% CI for HR: 5.83-18.93, p-value: < 0.001, respectively; Table 
2).  However, both left-sided radiotherapy and right-sided radiotherapy were associated 
with a significantly lower risk of cardiotoxicity by 0.16 and 0.30 times, respectively (HR: 
0.16, 95% CI for HR: 0.07-0.35, p-value: < 0.001 and HR: 0.30, 95% CI for HR: 0.16-
0.56, p-value: < 0.001, respectively).   
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In the multivariate Cox proportional-hazards regression analysis of the trastuzumab 
cohort, dyslipidemia was significantly associated with developing cardiotoxicity (HR: 
3.66, 95% CI for HR: 1.80-7.42, p-value: < 0.001; Table 3).  However, dyslipidemia had 
not been a significant risk factor in the anthracycline cohort (Table 2).  Again, left-sided 
radiotherapy and right-sided radiotherapy were both associated with a significantly lower 
risk of cardiotoxicity 0.23 and 0.31 times, respectively (HR: 0.23, 95% CI for HR: 0.10-
0.52, p-value: < 0.001 and HR: 0.31, 95% CI for HR: 0.15-0.64, p-value: 0.0017, 
respectively).  Although age was a significant risk factor in the unadjusted analysis, it 
was no longer a significant risk factor after adjusting for the other covariates.  Also, as 
seen in the Kaplan-Meier curves, anthracycline treatment at either of the cumulative dose 
levels (≤ 240 mg/m2 or > 240 mg/m2) did not significantly add to the risk of developing 
cardiotoxicity.     
In both cohorts, smoking history was not a significant risk factor in the univariate 
analysis (Tables 2 and 3).  However, it was a significant risk factor for developing 
cardiotoxicity after adjustment in the multivariate Cox proportional-hazards regression 
analysis (Tables 2 and 3).  In the anthracycline cohort, the adjusted hazard ratio was 2.82 
(95% CI for HR: 1.39-5.71, p-value: 0.0039).  In the trastuzumab cohort, the adjusted 
hazard ratio was 3.01 (95% CI for HR: 1.42-6.39, p-value: 0.0040).  In the anthracycline 
cohort, the smoking effect had been confounded by radiotherapy, which is associated 
with a lower risk of developing cardiotoxicity in our study.  In the trastuzumab cohort, 
dyslipidemia and age were found to be confounders.   
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A history of HTN, diabetes mellitus, and liver disease were not significant predictors of 
developing cardiotoxicity in either cohort (Tables 2 and 3).  Body mass index and a 
family history of cardiac disease were also not significant risk factors. 
Baseline imaging factors were evaluated in the anthracycline cohort.  For the sample of 
breast cancer patients receiving an anthracycline, the median LV EF was 63.0% (range: 
44.0 – 79.0), median PFR was 3.21 EDV/sec (range: 1.22 – 5.54), and median LV EDV 
was 101.0 mL (range: 46.0 – 253.0).  Abnormal baseline LV EF values were only 
observed in approximately 1% of the sample, while abnormal PFR and LV EDV levels 
were found in almost 14% and 16.5% of the sample, respectively.  The treatment 
subgroups did not differ significantly in their relative proportions of individuals with 
abnormal imaging factor levels (Table 4). 
Kaplan-Meier curves for univariate relationships between the baseline imaging factors 
and the outcome variable in the anthracycline cohort were also generated and compared.  
An enlarged left ventricular cavity on the baseline study (LV EDV ≥140 mL) was 
associated with a significantly reduced cardiotoxicity-free survival compared to a normal 
LV EDV less than 140 mL (p-value = 0.030: Figure 3a).  However, an abnormal PFR, 
indicating the presence of abnormal left ventricular relaxation, was not associated with a 
significantly different cardiotoxicity-free survival curve compared to a normal PFR (p = 
0.51: Figure 3b).  None of the five individuals with an abnormal LVEF developed 
cardiotoxicity, but there were not enough individuals with an abnormal LVEF to include 
in the univariate analyses.   
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In the univariate Cox proportional-hazards analysis, an abnormal PFR again was not 
significantly associated with cardiotoxicity in the anthracycline cohort.  However, those 
with an abnormal LV EDV had a significantly faster time to event than those with a 
normal LV EDV (HR: 1.80, 95% CI for HR: 1.05-3.08, p-value 0.032; Table 5).  After 
adjusting for cumulative anthracycline dose, additional treatment, chest radiotherapy, 
age, BMI, smoking history, family history of cardiac disease, and comorbidities 
(hypertension, diabetes, dyslipidemia, and liver disease) in a multivariate Cox 
proportional-hazards model, neither PFR nor LV EDV was significantly associated with 
cardiotoxicity (Table 5). 
It should be noted that a univariate Cox proportional-hazards analysis was carried out for 
the trastuzumab cohort as well.  However, neither PFR nor LV EDV was significantly 
associated with the development of cardiotoxicity, and therefore a multivariate analysis 
was not pursued.  Furthermore, there were not enough individuals with an abnormal 
LVEF from the trastuzumab cohort to include in the Cox proportional-hazards analyses. 
DISCUSSION 
Several important findings have resulted from the described investigations.  Some of the 
results confirm the conclusions of prior studies, while others challenge previously 
accepted beliefs.  The most unexpected of the latter were those of radiotherapy’s 
association with decreased rates of cardiotoxicity. 
Radiotherapy for breast cancer has been known to be potentially cardiotoxic, as 
supported by large meta-analyses of randomized trials (36, 37).  Both Cuzick et al. and 
the Early Breast Cancer Trialists’ Collaborative Group found that radiotherapy increased 
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cardiac or vascular mortality, respectively, when compared to breast cancer patients who 
didn’t receive radiotherapy (36, 37).  However, most of the trials included in these meta-
analyses utilized pre-modern radiotherapy techniques, which delivered greater amounts 
of radiation to the heart (30, 36, 37).  Since around 1985, more modern techniques such 
as image-guided therapy, reduction of field size, and respiratory gating have been used to 
reduce incidental cardiac irradiation (30).  
Tumor registry studies have demonstrated the impact of these changes in radiotherapy 
techniques over time (31, 38).  Giordano et al. examined three time periods during which 
patients were diagnosed with breast cancer: 1973-1979, 1980-1984, and 1985-1989 (31).  
During the first time period, they found that those who received left-sided radiotherapy 
had a 15-year mortality from ischemic heart disease of 13.1%, which was significantly 
different from the 10.2% 15-year mortality of those who received right-sided 
radiotherapy (31).  However, in the two latter time periods, no mortality differences were 
observed based on laterality of radiotherapy (31).  Furthermore, 15-year mortality 
decreased from 13.1% to 5.8% over the three time periods in those who received left-
sided radiotherapy.  These findings were presumably due at least in part to changing 
radiotherapy techniques that delivered less radiation to the heart (31).  Left-sided 
radiotherapy exposes the heart to a greater mean dose of radiation than right-sided 
radiotherapy due to the heart’s anatomic position (31).  However, Giordano’s findings 
suggest that with changing radiotherapy techniques over time, radiation exposure from 
left-sided radiotherapy has decreased such that it no longer confers a significantly higher 
risk of mortality from ischemic heart disease than right-sided radiotherapy.  Darby et al. 
had similar findings, with patients who received left-sided radiation between 1973 and 
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1982 experiencing significantly higher cardiac mortality rates than those who received 
right-sided radiation (38).  These differences were no longer significant in later time 
periods (38).  
Findings from other recent studies on breast cancer patients have been conflicting.  Hojris 
et al. performed an analysis of two randomized trials and found that radiotherapy did not 
increase the risk of ischemic heart disease, including myocardial infarction (39).  Doyle 
et al. focused their study on women ≥65 years of age and found that the risk of 
myocardial infarction likewise did not increase with receipt of radiotherapy, regardless of 
tumor laterality (40).  On the other hand, McGale et al. demonstrated in a prospective 
study that left-sided radiotherapy increases the risk for heart disease, relative to right-
sided radiotherapy, even for women diagnosed with breast cancer after 1990, a time 
during which they would have presumably been treated with more modern radiotherapy 
techniques (41).  According to Darby et al., even low doses of radiotherapy are associated 
with increased risk for ischemic heart disease (42).   
It should be mentioned, though, that these studies are not comparable to ours.  Unlike our 
study, the outcome of interest in many of these analyses was cardiac ischemia, which is 
presumably due to the mechanism of radiotherapy-induced cardiotoxicity.  Radiotherapy 
is known to induce atherosclerosis, particularly at higher doses (43).  Still, radiotherapy 
can also damage the microvasculature and promote inflammatory changes and interstitial 
fibrosis, potentially resulting in congestive heart failure (43).   
There have been studies that explored the effects of radiotherapy on subsequent 
development of heart failure or decreases in LVEF in breast cancer patients, though these 
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are not as frequent as those on cardiac ischemia (44-48).  Some have found that 
radiotherapy does not increase the risk of developing these cardiac outcomes (44, 46, 48), 
while others have found that they do increase the risk (45, 47).  However, these studies 
differed from ours in that not all of the patients received chemotherapy (44), patients 
were treated with radiotherapy in an earlier time period (1970-1986) (45), or the patients 
received trastuzumab and radiotherapy concurrently (46-48).  At our institution, 
trastuzumab is typically held during courses of radiotherapy.  
Our study is unique in that modern radiotherapy, regardless of laterality, was associated 
with significant improved cardiac outcomes in breast cancer patients who received an 
anthracycline and/or trastuzumab.  Reports of radiotherapy having a cardioprotective 
effect in breast cancer patients are rare.  We have only encountered one such report (49), 
and even then, it was not presented as one of the main results.  Specifically, Du et al. 
found that patients ≥ 65 years of age who receive radiotherapy are less likely to develop 
congestive heart failure than those who do not (49).   
Despite the lack of pre-existing evidence, the idea that radiotherapy can be 
cardioprotective is not entirely far-fetched.  Experiments have demonstrated that low 
doses of <1 Gy can have anti-inflammatory effects (50, 51).  In hypercholesterolemic 
mice, exposure to low doses of radiation is associated with reductions in the numbers and 
sizes of atherosclerotic lesions and in total serum cholesterol levels (52).  It is possible 
that the cardioprotective effect seen in our study was possibly due to a preconditioning 
effect, akin to ischemic preconditioning where brief periods of ischemia can protect 
against more prolonged insults (53).  Low doses of radiation to the heart may have 
protected it against further insults from chemotherapy and/or trastuzumab.   
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Still, the cardioprotective effects seen in our study should be considered with caution, as 
there may be potential confounding with factors such as additional treatment type.  In the 
anthracycline cohort (excluding those who got bilateral radiotherapy since they had also 
been excluded from the multivariate analyses), 20 (27%) of the 74 patients treated with 
trastuzumab received left-sided radiotherapy.  However, 152 (38%) of the 400 patients 
who weren’t treated with trastuzumab received left-sided radiotherapy.  This bias almost 
reaches significance (Fisher’s exact test p-value = 0.09).  Given that trastuzumab (as will 
be further discussed later) exhibited a very significant cardiotoxic effect in our study, this 
potential confounding finding could thus have produced the cardioprotective effect. 
However, this reasoning fails when applied to right-sided radiotherapy.  In the same 
anthracycline cohort (again excluding those who received bilateral radiotherapy), 24 
(32%) of the 74 patients treated with trastuzumab underwent right-sided radiotherapy.  
Similarly, 136 (34%) of the 400 patients who were not treated with trastuzumab were 
given right-sided radiotherapy (Fisher’s exact test p-value = 0.89).  There is no clear bias 
in this case that could explain the significant cardioprotective effect exhibited by right-
sided radiotherapy.   
Furthermore, the trastuzumab cohort does not lend itself to a similar evaluation of 
potential confounding with additional treatment type since all of the patients had received 
trastuzumab.  As will be discussed later, additional anthracycline treatment is not 
associated with increased risk of cardiotoxicity in this cohort.  Therefore, any differences 
in the proportions of patients given radiotherapy who did or did not receive anthracycline 
treatment in addition to trastuzumab is not of relevance in this particular discussion.   
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Though the observed beneficial effects cannot be completely attributed to confounding 
by additional treatment, the bias seen in the anthracycline cohort is a reminder of the 
limitations of a retrospective study.  There may be several other confounding factors that 
we were unable to adjust for in this study.  As such, it would be premature to definitely 
conclude that radiotherapy is cardioprotective based on our findings.  Rather, until our 
findings can be reproduced by other studies and trials, emphasis should be placed instead 
on the lack of a significant cardiotoxic effect associated with radiotherapy.  The absence 
of this relationship in our results suggests that previously accepted beliefs regarding 
radiotherapy’s harmful cardiac effects may be outdated.  There is a need for newer 
studies determining the effects of modern radiotherapy on the heart in the setting of 
contemporary breast cancer treatments.        
As discussed above, another finding of our study is that certain treatment agents add to 
cardiotoxicity risk.  It has been well established that trastuzumab increases the risk of 
developing cardiotoxicity when given to patients who also receive anthracycline, as we 
confirmed in our study (48, 49, 54, 55).  However, anthracycline at either cumulative 
dose levels (≤240 mg/m2 or >240 mg/m2) did not add to the risk of developing 
cardiotoxicity in the trastuzumab cohort, when compared to the no-anthracycline 
subgroup.  This is contrary to previous findings of increased risk with treatments based 
on both anthracycline and trastuzumab (56), and we suspect that the negative finding was 
perhaps partly due to a treatment bias.  Patients who were not given both trastuzumab and 
anthracycline may have had a greater predisposition for developing cardiotoxicity than 
those who did receive both.  There may have been aspects of their medical history that 
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discouraged clinicians from treating patients who had to receive trastuzumab in addition 
to an anthracycline. 
Similarly, the 3-year cumulative incidence of cardiac events was higher in the 
anthracycline plus trastuzumab subgroup of the anthracycline cohort than in the 
anthracycline-only subgroup (43.42 cardiac events per 100 people versus 5.91 cardiac 
events per 100 people).  However, in the trastuzumab cohort, there was no significant 
difference between the trastuzumab without anthracycline (52.27 cardiac events per 100 
people) and trastuzumab plus anthracycline subgroups (43.42 cardiac events per 100 
people) (p = 0.46).   
The incidences observed in our study are generally higher than those published in other 
studies.  For example, the observed 3-year cumulative incidences of heart failure or 
cardiomyopathy in a retrospective study of elderly women were 28.2, 15.3, and 26.7 per 
100 patients in its anthracycline plus trastuzumab, anthracycline (without trastuzumab), 
and trastuzumab (without anthracycline) groups, respectively (54).  The Herceptin 
Adjuvant (HERA) trial found the incidence of left ventricular dysfunction at 3.6 years of 
follow-up to be just 9.8% in those who received trastuzumab (57).  The North Central 
Center Treatment Group (NCCTG) N9831 trial observed even lower cumulative 
incidences of 0.3% in the anthracycline (without trastuzumab) group and 2.8% in the 
sequential anthracycline plus trastuzumab (plus paclitaxel) group at 3 years (58).  
Similarly, the 5-year cumulative incidence in the National Surgical Adjuvant Breast and 
Bowel Project (NSABP) B-31 trial was 0.9% in the anthracycline (without trastuzumab) 
group and 3.8% in the sequential anthracycline plus trastuzumab/paclitaxel group (58).  
The Breast Cancer International Research Group 006 trial likewise observed lower 
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incidences of cardiotoxicity despite having a longer mean length of follow-up (56).  
However, unlike our study, these studies did not include subclinical cardiotoxicity in their 
definition of a cardiac endpoint (54) or excluded those with cardiovascular disease (57-
59).  We suspect that our findings are closer to the true incidence of cardiotoxicity in 
anthracycline and/or trastuzumab-treated breast cancer patients.   
Bevacizumab was another therapeutic agent that significantly increased the risk of 
developing cardiotoxicity in the anthracycline cohort.  The data regarding this agent’s 
cardiac effects are mixed, with some studies finding that it increases the risk for 
congestive heart failure (60, 61), while others reporting that it does not (62).  It will be 
important to study further bevacizumab’s cardiac toxicities as it has been an agent of 
interest due to findings that it increases the pathologic complete response rate and 
improves progression-free survival (63, 64). 
Additionally, we found that dyslipidemia was a significant risk factor of cardiotoxicity in 
the trastuzumab cohort.  A positive smoking history was a significant predictor in both 
the trastuzumab and anthracycline cohorts.  Previous studies, including the NSABP B-31 
and HERA trials, did not find them to be significant risk factors for the development of 
CHF (48, 65, 66).  However, smoking was a positive predictor for trastuzumab mediated 
cardiotoxicity in a retrospective study (67).  A speckle tracking echocardiographic study 
also found that smoking negatively affected longitudinal strain in breast cancer patients 
who received chemotherapy (68).  It is suspected that smoking may contribute to 
cardiotoxicity by increasing oxidative stress (68).  In the majority of these previous 
studies, it is unclear what was considered to be a positive smoking history.  In our study, 
current smokers and those who had quit within the year prior to their baseline ERNA 
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were considered to have a positive smoking history.  Patients who had quit smoking more 
than a year prior to their baseline ERNA were considered to have a negative smoking 
history.  As such, our findings suggest that recent or current smoking is a potential target 
for risk reduction and lifestyle modification, as well as dyslipidemia. 
A cumulative anthracycline dose > 240 mg/m
2
 (240 mg/m
2
 is the cumulative dose 
typically used to treat breast cancer) was a negative predictor for cardiotoxicity.  
However, it has been well established that higher doses, particularly those greater than 
550 mg/m
2
, are associated with increased risk (15).  Our finding is likely due to the study 
not being sufficiently powered to detect a difference between the two levels.  Only a 
small proportion of patients had received cumulative anthracycline doses > 240 mg/m
2
 
(7.28% in the anthracycline cohort and 7.04% of those who received anthracycline in the 
trastuzumab cohort: Tables 1a and 1b).   Furthermore, the highest cumulative 
anthracycline dose in the anthracycline cohort was just 450 mg/m
2
, while the highest 
cumulative anthracycline dose in the trastuzumab cohort was 310 mg/m
2
. 
An abnormal baseline LV EDV was significantly associated with cardiotoxicity in the 
univariate Cox proportional-hazards analysis of the anthracycline cohort.  However, after 
adjustment for various patient and treatment-related factors, the association was no longer 
significant.   An abnormal baseline PFR, a marker of diastolic dysfunction, was not 
significantly associated with cardiotoxicity in either the univariate or multivariate 
analysis.  Unfortunately, there are no other studies on abnormal baseline ERNA imaging 
factors that predict cardiotoxicity.  However, there have been studies that have assessed 
various imaging parameters obtained during cancer treatment or post-treatment as 
subclinical predictors of subsequent significant changes in LVEF or heart failure (in 
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contrast to assessing pre-treatment ERNA imaging parameters as predictors of 
developing cardiotoxicity such as in our study).  Though the questions addressed by these 
studies and ours are fundamentally different, we can use the findings of the former as a 
starting point for discussion. 
There have been studies that have focused on early diastolic abnormalities as potential 
predictors of cardiotoxicity.  A case series of three patients who received doxorubicin 
found that a decrease in the PFR preceded development of changes in LVEF and the 
development of CHF (69).  The authors therefore proposed PFR as a more sensitive 
marker of early cardiotoxicity than the conventional marker, LVEF (69).  Hashimoto et 
al. also found that the PFR was significantly lower in pediatric patients who received 
anthracycline compared to a control group, even though there was no significant 
difference in LVEF between the two groups (70).  However, they did not determine 
whether this potential marker of subclinical cardiotoxicity could be used as a predictor of 
subsequent changes in LVEF or CHF (70).  
The aforementioned studies suggest that chemotherapy-induced cardiotoxicity may be a 
step-wise process whereby the myocardium undergoes several phases of injury, with 
diastolic changes perhaps preceding systolic changes.  If so, it would seem sensible that 
patients with baseline abnormalities in PFR or LV EDV prior to beginning anthracycline- 
or trastuzumab-based treatment would be predisposed to developing cardiotoxicity (as 
defined by significant declines LVEF or CHF manifestations) due to pre-existing 
diastolic abnormalities.  However, this hypothesis did not hold up in our study.  This may 
be at least partly explained by some important differences between previous studies and 
ours.  Namely, the cancer types being treated in previous studies were varied and 
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included diagnoses such as rhabdomyosarcoma, acute lymphoblastic leukemia, Wilm’s 
tumor, breast carcinoma, and small cell lung carcinoma (69, 70).  Therefore, the 
cumulative doses of anthracycline that patients received in the case series (69) (mean: 
385 ± 105 mg/m
2
) and the study by Hashimoto et al. (70) (mean: 305 ± 236 mg/m
2
) were 
on average higher than the cumulative anthracycline doses that our patients received 
(mean: 241.3 ± 24.75 mg/m
2
).  It may be that the typical cumulative anthracycline doses 
administered during the treatment of breast cancer, such as in our study sample, are not 
high enough to cause significant enough additional diastolic damage.  Regardless, our 
findings suggest that a PFR < 2.5 EDV/sec and an LV EDV ≥140 mL are not strong 
predictors of cardiotoxicity in breast cancer patients who receive anthracycline- and/or 
trastuzumab-based treatments. 
It would be reasonable to expect an abnormal baseline LVEF to be a predictor of 
cardiotoxicity, particularly since the definition of cardiotoxicity in our study includes 
significant declines in LVEF.  However, a limitation of our study was that there were 
only a few patients with an abnormal baseline LVEF, and meaningful statistical analyses 
of their potential implications could not be carried out.  Based on a recent systematic 
review, an early 10%-15% reduction in peak systolic global longitudinal strain (GLS), as 
determined by speckle tracking echocardiography (STE), seems to be a valuable predictor 
of subsequent LVEF declines or heart failure in patients who received trastuzumab and/or 
anthracycline (32).   Such findings highlight the importance of studying baseline LVEF 
as a potential predictor of cardiotoxicity in future studies that are sufficiently powered to 
do so.    
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Future studies should also focus on further examination of the effects of radiotherapy, 
bevacizumab, dyslipidemia, and smoking on risk of developing cardiotoxicity in breast 
cancer patients.  They are potentially important for risk stratification and reduction.  In 
particular, our findings on radiotherapy illustrate that its effects are not simply 
cardiotoxic, but that it has a complicated relationship with other treatment factors.  It 
seems that modern radiotherapy techniques that deliver low doses of radiation to the 
heart, when given after relatively low cumulative doses of anthracycline typical of 
standard breast cancer chemotherapy, can be potentially cardioprotective against left 
ventricular systolic dysfunction and heart failure.  However, we can only be speculative 
at this point given the potential for confounding factors and instead place more 
confidence on the lack of a significant cardiotoxic effect associated with radiotherapy.  
More studies are necessary to assess the validity of our results and further explore the 
relationship between low doses of radiotherapy and development of congestive heart 
failure or systolic dysfunction in breast cancer patients.  Future investigations should 
stratify radiotherapy not just by laterality but also by region and total dose of radiation to 
the heart.  It will also be important to determine whether or not the potential 
cardioprotective effects of radiotherapy seen in our study, if reproducible, are long-term 
and persist beyond the follow-up duration of our study.  In addition, it will be important 
to see if there is a linear relationship between cigarette pack-years and risk of developing 
cardiotoxicity and if there is a minimum pack-year level beyond which risk begins to 
increase.  Elucidating the effects of statin therapy and disease control on dyslipidemia’s 
contributions to cardiotoxicity will also be important. 
Study limitations 
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The greatest limitation of our study was that it was retrospective.  However, we attempted 
to minimize confounding factors and bias by adjusting for many potential confounders 
and appropriately limiting our sample.  Patients who had previously received 
chemotherapy and/or radiotherapy or were diagnosed with a cancer that would have 
required either were excluded.  Secondly, the study relied on the identification of a cohort 
of patients based on determination of the baseline LVEF by ERNA.  Therefore, patients 
whose baseline LVEF was determined by echocardiogram were not included.  However, 
based on referral patterns at our institution, we have no reason to believe that there would 
be significant baseline differences between those who underwent an ERNA versus an 
echocardiogram.  As mentioned previously, the small sample size of patients with an 
abnormal baseline LVEF was another limitation that prevented meaningful statistical 
analysis of its association with developing cardiotoxicity. 
Conclusions 
In both the anthracycline and trastuzumab cohorts of breast cancer patients, radiotherapy 
was associated with a lower risk of a subsequent decrease in LVEF or development of 
CHF.  However, there may have been confounding factors that this study could not adjust 
for, and emphasis should instead be placed on the lack of a significant cardiotoxic effect 
associated with radiotherapy.  Dyslipidemia and a positive smoking history are 
significant predictors for the development of cardiac events and potential targets for risk 
reduction.  Trastuzumab and bevacizumab independently increased the risk of 
cardiotoxicity in patients who received an anthracycline.  Abnormal baseline LV EDV 
and PFR do not appear to be strong predictors of anthracycline- or trastuzumab-induced 
cardiotoxicity.  Patients with the aforementioned significant risk factors may benefit from 
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more stringent cardiac monitoring for earlier detection of subclinical myocardial injury so 
that the benefits of receiving effective breast cancer treatments such as anthracyclines or 
trastuzumab will outweigh the costs of cardiotoxicity.  Future studies are necessary to 
establish such benefits and determine the optimal monitoring parameters and frequency. 
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FIGURES 
 
Figure 1a. Kaplan-Meier Analysis of the Incidence of Cardiotoxicity in the 
Anthracycline Cohort Based on Additional Treatment 
 
 
Figure 1b. Kaplan-Meier Analysis of the Incidence of Cardiotoxicity in the 
Anthracycline Cohort Based on Radiotherapy Location 
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Figure 2a. Kaplan-Meier Analysis of the Incidence of Cardiotoxicity in the 
Trastuzumab Cohort Based on Additional Treatment 
 
 
 
Figure 2b. Kaplan-Meier Analysis of the Incidence of Cardiotoxicity in the 
Trastuzumab Cohort Based on Radiotherapy Location 
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Figure 3a. Kaplan-Meier Analysis of the Incidence of Cardiotoxicity in the 
Anthracycline Group Based on Left Ventricular End-Diastolic Volume (LV EDV) 
 
 
Figure 3b. Kaplan-Meier Analysis of the Incidence of Cardiotoxicity in the 
Anthracycline Group Based on Peak Filling Rate (PFR) 
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TABLES 
Table 1a. Descriptive Summary of the Anthracycline Cohort 
 
All Breast Cancer 
Patients Receiving 
Anthracycline 
Anthracycline 
- Bevacizumab 
- Trastuzumab 
Anthracycline 
+ 
Bevacizumab 
Anthracycline 
+ 
Trastuzumab 
p-value 
Characteristic n = 496 n = 389 n = 30 n  = 76  
Incidence Rate (events/person-month) 0.0032 0.0015 0.0068 0.014 <0.001* 
3-Year Cumulative Incidence (per 100 
people) 
12.70 5.91 23.33 43.42 <0.001* 
Cardiotoxic Event      
     Event 69 (13.9) 27 (6.94) 7 (23.33) 35 (46.05) <0.001* 
     No Event 427 (86.1) 362 (93.06) 23 (76.67) 41 (53.95)  
Cumulative Anthracycline Dose 
(mg/m
2
)
  
    
     Mean ± SD 241.3 ± 24.75 240.5 ± 23.08 254.4 ± 45.76 239.9 ± 19.11 0.013* 
     ≤ 240 420 (92.72) 330 (93.48) 24 (82.76) 66 (92.96) 0.11 
     > 240 33 (7.28) 23 (6.52) 5 (17.24) 5 (7.04)  
Radiotherapy 
 
    
     Left-sided only 172 (34.89) 140 (36.18) 12 (40.00) 20 (26.67) 0.081 
     Right-sided only 161 (32.66) 126 (32.56) 10 (33.33) 24 (32.00)  
     Both left- and right-sided  18 (3.65) 14 (3.62) 3 (10.00) 1 (1.33)  
     None 142 (28.80) 107 (27.65) 5 (16.67) 30 (40.00)  
Age (years)  
 
    
     Mean ± SD 50.84 ± 9.65 51.27 ± 9.59 48.53 ± 10.29 49.47 ± 9.58  0.13 
     ≤ 65 462 (93.15) 360 (92.54) 29 (96.67) 72 (94.74) 0.75 
     > 65 34 (6.85) 29 (7.46) 1 (3.33) 4 (5.26)  
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Table 1a continued 
BMI 
 
    
     Mean ± SD 27.97 ± 6.88 28.14 ± 7.00 27.54 ± 5.47 27.06 ± 6.67 0.45 
     Normal 183 (37.97) 144 (37.70) 9 (31.03) 30 (42.86) 0.76 
     Overweight 156 (32.37) 123 (32.20) 12 (41.38) 21 (30.00)  
     Obese 143 (29.67) 115 (30.10) 8 (27.59) 19 (27.14)  
Hypertension      
     Yes 149 (30.41) 123 (31.95) 9 (30.00) 17 (22.67) 0.28 
     No 341 (69.59) 262 (68.05) 21 (70.00) 58 (77.33)  
Diabetes Mellitus      
     Yes 44 (8.96) 36 (9.33) 1 (3.33) 7 (9.33) 0.69 
     No 447  (91.04) 350 (90.67) 29 (96.67) 68 (90.67)  
Dyslipidemia      
     Yes 114 (23.27) 91 (23.64) 5 (16.67) 18 (24.00) 0.68 
     No 376 (76.73) 294 (76.36) 25 (83.33) 57 (76.00)  
History of Smoking      
     Yes 80 (16.33) 61 (15.89) 6 (20.00) 13 (17.33) 0.74 
     No 410 (83.67) 323 (84.11) 24 (80.00) 62 (82.67)  
Family History of Cardiac Disease      
     Yes 230 (46.75) 185 (47.80) 12 (40.00) 32 (43.24) 0.58 
     No 262 (53.25) 202 (52.20) 18 (60.00) 42 (56.76)  
Coronary Artery Disease      
     Yes 5 (1.02) 4 (1.04) 0 (0.00) 1 (1.33) 0.70 
     No 485 (98.98) 381 (98.96) 30 (100.00) 74 (98.67)  
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Table 1a continued 
Atrial fibrillation      
     Yes 1 (0.20) 1 (0.26) 0 (0.00) 0 (0.00) 1.0 
     No 489 (99.80) 384 (99.74) 30 (100.00) 75 (100.00)  
     No 489 (99.80) 385 (100.00) 30 (100.00) 74 (98.67)  
Liver Disease      
     Chronic 2 (0.41) 2 (0.52) 0 (0.00) 0 (0.00) 0.95 
     Transient 43 (8.78) 34 (8.83) 3 (10.00) 6 (8.00)  
     None 445 (90.82) 349  (90.65) 27 (90.00) 69 (92.00)  
Stroke/TIA      
     Yes 6 (1.22) 4 (1.04) 0 (0.00) 2 (2.67) 0.49 
     No 485 (98.78) 382 (98.96) 30 (100.00) 73 (97.33)  
Chronic renal failure      
     Yes 5 (1.02) 4 (1.04) 0 (0.00) 1 (1.33) 0.70 
     No 485 (98.98) 381 (98.96) 30 (100.00) 74 (98.67)  
Note: Data are n (%) of persons for whom data are available.  Percentages may not sum to one hundred due to rounding. 
* Statistically significant at the p < 0.05 level
  
BMI = body mass index; TIA = transient ischemic attack; SD = standard deviation
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Table 1b. Descriptive Summary of the Trastuzumab Cohort 
 
All Breast Cancer Patients 
Receiving Trastuzumab 
Trastuzumab 
without 
Anthracycline  
Trastuzumab 
with 
Anthracycline 
p-value 
Characteristic n = 134 n = 57 n  = 76  
Incidence Rate (events/person-
month) 
0.015 0.017 0.014 0.46 
3-Year Cumulative Incidence (per 
100 people) 
42.54 52.27 43.42 0.46 
Cardiotoxic Event     
     Event 59 (44.03) 23 (40.35) 35 (46.05) 0.63 
     No Event 75 (55.97) 34 (59.65) 41 (53.95)  
Radiotherapy     
     Left-sided only 38 (28.79) 18 (31.58) 20 (26.67) 0.42 
     Right-sided only 35 (26.52) 11 (19.30) 24 (32.00)  
     Both left- and right-sided  2 (1.52) 1 (1.75) 1 (1.33)  
     None 57 (43.18) 27 (47.37) 30 (40.00)  
Age (years)      
     Mean ± SD 52.01 ± 10.66 55.44 ± 11.24  49.47 ± 9.58 0.0017* 
     ≤ 65 122 (91.04) 49 (85.96) 72 (94.74) 0.12 
     > 65 12 (8.96) 8 (14.04) 4 (5.26)  
BMI     
     Mean ± SD 26.92 ± 6.28 26.69 ± 5.86 27.06 ± 6.67 0.74 
     Normal 55 (42.97) 25 (43.86) 30 (42.86) 0.75 
     Overweight 42 (32.81) 21 (36.84) 21 (30.00)  
     Obese 31 (24.22) 11 (19.30) 9 (27.14)  
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Table 1b continued 
Hypertension     
     Yes  38 (28.57) 21 (36.84) 17 (22.67) 0.11 
     No 95 (71.43) 36 (63.16) 58 (77.33)  
Diabetes Mellitus     
     Yes 10 (7.52) 3 (5.26) 7 (9.33) 0.51 
     No 123 (92.48) 54 (94.74) 68 (90.67)  
Dyslipidemia     
     Yes 33 (24.81) 15 (26.32) 18 (24.00) 0.92 
     No 100 (75.19) 42 (73.68) 57 (76.00)  
History of Smoking     
     Yes 24 (18.05) 11 (19.30) 13 (17.33) 0.95 
     No 109 (81.95) 46 (80.70) 62 (82.67)  
Family History of Cardiac Disease     
     Yes 61 (47.67) 29 (54.72) 32 (43.24) 0.27 
     No 67 (52.34) 24 (45.28) 42 (56.76)  
Coronary Artery Disease     
     Yes 2 (1.50) 1 (1.75) 1 (1.33) 1.0 
     No 131 (98.50) 56 (98.25) 74 (98.67)  
Atrial fibrillation     
     Yes 1 (0.75) 1 (1.75) 0 (0.00) 0.43 
     No 132 (99.25) 56 (98.25) 75 (100.00)  
Peripheral vascular disease     
     Yes 1 (0.75) 0 (0.00) 1 (1.33) 1.0 
     No 132 (99.25) 57 (100.00) 74 (98.67)  
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Table 1b continued 
Liver Disease     
     Chronic 1 (0.75) 1 (1.75) 0 (0.00) 0.28 
     Transient 8 (6.02) 2 (3.51) 6 (8.00)  
     None 124 (93.23) 54 (94.74) 69 (92.00)  
Stroke/TIA     
     Yes 3 (2.26) 1 (1.75) 2 (2.67) 1.0 
     No 130 (97.74) 56 (98.25) 73 (97.33)  
Chronic renal failure     
     Yes 7 (5.26) 6 (10.53) 1 (1.33) 0.042* 
     No 126 (94.74) 51 (89.47) 74 (98.67)  
Note: Data are n (%) of persons for whom data are available.  Percentages may not sum to one hundred due to rounding. 
* Statistically significant at the p < 0.05 level 
BMI = body mass index; TIA = transient ischemic attack; SD = standard deviation 
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Table 2. Univariate and Multivariate Cox Proportional-Hazards Regression Analysis of the Anthracycline Cohort  
       
Characteristics Unadjusted HR (95% CI) p-value Adjusted HR  (95% CI) p-value 
Anthracycline Dose       
     ≤ 240 mg/m2 Reference ---  Reference ---  
     > 240 mg/m
2
 1.68 (0.76, 3.68) 0.17 1.72 (0.70, 4.19) 0.24 
Additional Treatment       
     None Reference ---  Reference ---  
     Bevacizumab 3.56 (1.55, 8.20) 0.0028* 4.70 (1.78, 12.44) 0.0018* 
     Trastuzumab 7.96 (4.81, 13.18) <0.001* 10.51 (5.83, 18.93) <0.001* 
Radiotherapy       
     None Reference ---  Reference ---  
     Left-Sided Only 0.19 (0.10, 0.37) <0.001* 0.16 (0.07, 0.35) <0.001* 
     Right-Sided Only 0.32 (0.18, 0.56) <0.001* 0.30 (0.16, 0.56) <0.001* 
Age       
     ≤ 65 Reference ---  Reference ---  
     > 65 1.71 (0.78, 3.75) 0.18 1.67 (0.58, 4.83) 0.34 
BMI       
     Normal Reference ---  Reference ---  
     Overweight 0.93 (0.53, 1.62) 0.79 0.77 (0.40, 1.48) 0.43 
     Obese 0.77 (0.42, 1.41) 0.39 0.96 (0.44, 2.08) 0.91 
Hypertension 0.64 (0.36, 1.14) 0.13 0.85 (0.39, 1.86) 0.68 
Diabetes 0.79 (0.32, 1.97) 0.62 0.58 (0.19, 1.78) 0.34 
Dyslipidemia 1.18 (0.69, 2.02) 0.55 1.69 (0.87, 3.32) 0.12 
Smoking History 1.42 (0.79, 2.56) 0.24 2.82 (1.39, 5.71) 0.0039* 
Family History of Cardiac      
     Disease 
0.96 (0.60, 1.54) 0.87 1.13 (0.65, 1.98) 0.66 
Liver Disease 0.98 (0.42, 2.26) 0.95 1.01 (0.36, 2.83) 0.98 
       
* Statistically significant at the p < 0.05 level; HR = hazard ratio; CI = confidence interval; BMI = body mass index 
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Table 3. Univariate and Multivariate Cox Proportional-Hazards Regression Analysis of the Trastuzumab Cohort 
                
Characteristics Unadjusted HR (95% CI) p-value Adjusted HR  (95% CI) p-value 
Anthracycline Dose       
     0 mg/m
2
 Reference ---  Reference ---  
     ≤ 240 mg/m2 1.03 (0.60, 1.77) 0.92 1.29 (0.68, 2.46) 0.44 
     > 240 mg/m
2
 2.24 (0.76, 6.55) 0.14 2.49 (0.59, 10.5) 0.21 
Radiotherapy       
     None Reference ---  Reference ---  
     Left-Sided Only 0.27 (0.13, 0.56) <0.001* 0.23 (0.10, 0.52) <0.001* 
     Right-Sided Only 0.49 (0.27, 0.91) <0.001* 0.31 (0.15, 0.64) 0.0017* 
Age       
     ≤ 65 Reference ---  Reference ---  
     > 65 3.97 (1.99, 7.91) <0.001* 2.31 (0.78, 6.80) 0.13 
BMI       
     Normal Reference ---  Reference ---  
     Overweight 0.84 (0.46, 1.54) 0.57 0.61 (0.29, 1.28) 0.19 
     Obese 0.95 (0.50, 1.82) 0.88 0.85 (0.35, 2.05) 0.71 
Hypertension 1.12 (0.64, 1.98) 0.68 1.35 (0.55, 3.36) 0.51 
Diabetes 0.59 (0.19, 1.89) 0.38 0.31 (0.07, 1.48) 0.14 
Dyslipidemia 2.03 (1.17, 3.52) 0.011* 3.66 (1.80, 7.42) <0.001* 
Smoking History 1.69 (0.93, 3.10) 0.087 3.01 (1.42, 6.39) 0.0040* 
Family History of Cardiac      
     Disease 
0.79 (0.47, 1.33) 0.37 0.85 (0.44, 1.62) 0.62 
Liver Disease 1.49 (0.59, 3.73) 0.40 2.07 (0.63, 6.73) 0.23 
      
* Statistically significant at the p < 0.05 level; HR = hazard ratio; CI = confidence interval; BMI = body mass index 
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Table 4. Baseline Imaging Parameters: Descriptive Summary of Anthracycline Cohort 
      
 
All Breast 
Cancer Patients 
Receiving 
Anthracycline 
Anthracycline - 
Bevacizumab - 
Trastuzumab 
Anthracycline 
+ 
Bevacizumab 
Anthracycline 
+ 
Trastuzumab 
p-value 
Characteristic n = 496 n = 389 n = 30 n  = 76  
Peak Filling Rate (PFR) (EDV/sec)      
     Normal (≥ 2.5) 427 (86.26) 336 (86.60) 27 (90.00) 64 (84.21) 0.75 
     Abnormal (< 2.5) 68  (13.74) 52 (13.40) 3 (10.00) 12 (15.79)  
Left Ventricular End-Diastolic Volume 
(LV EDV) (ml) 
   
  
     Normal (< 140) 414 (83.47) 324 (83.29) 27 (90.00) 62 (81.58) 0.62 
     Abnormal (≥ 140) 82 (16.53) 65 (16.71) 3 (10.00) 14 (18.42)  
Left ventricular ejection fraction 
(LVEF) (%) 
   
  
     Normal (≥ 50) 491 (98.99) 386 (99.23) 30 (100.00) 75 (98.68) 0.62 
     Abnormal (< 50) 5 (1.01) 3 (0.77) 0 (0.00) 1 (1.32)  
      
Note: Data are n (%) of persons for whom data are available.  Percentages may not sum to one hundred due to rounding. 
* Statistically significant at the p < 0.05 level
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Table 5.  Baseline Imaging Parameters: Univariate and Multivariate Cox Proportional-Hazards Regression Analysis of the 
Anthracycline Cohort 
                
Baseline Imaging Parameter  Unadjusted HR (95% CI) p-value Adjusted HR  (95% CI) p-value 
Peak Filling Rate (PFR) (EDV/sec)       
     Normal (≥ 2.5) Reference ---  Reference ---  
     Abnormal (< 2.5) 0.78 (0.37, 1.64) 0.51 0.74 (0.29, 1.90) 0.53 
Left Ventricular End-Diastolic Volume (LV 
EDV) (ml) 
      
     Normal (< 140) Reference ---  Reference ---  
     Abnormal (≥ 140) 1.80 (1.05, 3.08) 0.032* 1.28 (0.63, 2.61) 0.50 
       
* Statistically significant at the p < 0.05 level 
HR = hazard ratio; CI = confidence interval 
Adjusted for cumulative anthracycline dose, additional treatment, chest radiotherapy, age, BMI, smoking history, family history of 
cardiac disease, and comorbidities (hypertension, diabetes, dyslipidemia, and liver disease) in a multivariate Cox proportional-hazards 
model 
 
 
